Advertisement

Reactions Weekly

, Volume 1730, Issue 1, pp 259–259 | Cite as

Protein tyrosine kinase inhibitors

Drug resistance in lung adenocarcinoma: 2 case reports
Case report
  • 15 Downloads

Reference

  1. Giroux-Leprieur E, et al. Combination of Crizotinib and Osimertinib or Erlotinib Might Overcome MET-Mediated Resistance to EGFR Tyrosine Kinase Inhibitor in EGFR-Mutated Adenocarcinoma. Journal of Thoracic Oncology 13: e232-e234, No. 11, Nov 2018. Available from: URL: http://doi.org/10.1016/j.jtho.2018.07.012 - France

Copyright information

© Springer Nature Switzerland AG 2018

Personalised recommendations